Marcus Low

Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation

Masanori Baba, Dominique Schols, Erik De Clercq et al. · Antimicrobial Agents and Chemotherapy · 1990 · 107 citations · Full text

Life Sciences, Immunology, Medicinal Chemistry +8

Sulphated Polymers are Potent and Selective Inhibitors of Various Enveloped Viruses, Including Herpes Simplex Virus, Cytomegalovirus, Vesicular Stomatitis Virus, Respiratory Syncytial Virus, and Toga-, Arena- and Retroviruses

Dominique Schols, Erik De Clercq, Jan Balzarini et al. · Antiviral chemistry & chemotherapy · 1990 · 92 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12

New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines

Fátima Suleman, Marcus Low, Suerie Moon et al. · BMJ · 2020 · 42 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +16

Shorter TB treatment regimens should be safer as well

Oxana Rucsineanu, P. Agbassi, Rosa María Blanca Herrera et al. · Public Health Action · 2023 · 12 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Challenges in TB regimen development: preserving evidentiary standards for regulatory decisions and policymaking

Lorenzo Guglielmetti, Marcus Low, Lindsay McKenna · Expert Review of Anti-infective Therapy · 2020 · 10 citations · Full text

Nursing, Infectious Disease Control, Health Systems Governance +1